Abstract
The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Current Drug Targets
Title: Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Volume: 11 Issue: 7
Author(s): Aude-Helene Capietto, Samarh Keirallah, Emilie Gross, Nicolas Dauguet, Emilie Laprevotte, Christine Jean, Julie Gertner-Dardenne, Christine Bezombes, Anne Quillet-Mary, Mary Poupot, Loic Ysebaert, Guy Laurent and Jean-Jacques Fournie
Affiliation:
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Abstract: The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Export Options
About this article
Cite this article as:
Capietto Aude-Helene, Keirallah Samarh, Gross Emilie, Dauguet Nicolas, Laprevotte Emilie, Jean Christine, Gertner-Dardenne Julie, Bezombes Christine, Quillet-Mary Anne, Poupot Mary, Ysebaert Loic, Laurent Guy and Fournie Jean-Jacques, Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320845
DOI https://dx.doi.org/10.2174/138945010791320845 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC
Current Molecular Medicine The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Current Cancer Therapy Reviews Thymic Nurse Cells Participate in Heterotypic Internalization and Repertoire Selection of Immature Thymocytes; Their Removal from the Thymus of Autoimmune Animals May be Important to Disease Etiology
Current Molecular Medicine Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents An Advanced Computational Evaluation for the Most Biologically Active Enantiomers of Chiral Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Topoisomerase Enzymes as Therapeutic Targets for Cancer Chemotherapy
Medicinal Chemistry Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases
Current Vascular Pharmacology Growth Factors, Cytokines and Dendritic Cell Development
Current Pharmaceutical Design Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Structural Insight of NICD-MAML Interactions: Virtual Screening, Docking and Molecular Dynamics Study for Identification of Potential Inhibitor
Letters in Drug Design & Discovery Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Current Pharmaceutical Design Medical Treatment of Malignancy-Associated Hypercalcemia
Current Medicinal Chemistry The Cytotoxic and Mechanistic Effects of Aaptamine on Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism A Structure-Function Perspective of Jak2 Mutations and Implications for Alternate Drug Design Strategies: The Road not Taken
Current Medicinal Chemistry